MFU-V (Ultherapy) skin tightening: 2026 evidence review

Microfocused ultrasound with visualization (MFU-V), commercially known as the Ulthera System, is a non-invasive energy-based device used for lifting and tightening of the face and neck and for improving the appearance of décolletage wrinkles. The technology delivers focused ultrasound energy through the epidermis to create discrete thermal coagulation points at defined depths in the deep dermis and superficial musculoaponeurotic system (SMAS), triggering neocollagenesis and elastin remodeling over the months that follow. Two large 2024–2025 narrative reviews covering more than 60 studies summarize the current evidence base for MFU-V across skin quality outcomes [1][2].

This article reviews what is supported by the clinical evidence in 2026: mechanism, expected timeline, comparative outcomes with other energy devices, adverse events, and patient selection. It is intended as a balanced summary for patients and clinicians, not as medical advice. Consult a board-certified dermatologist before starting or changing a treatment plan.

How MFU-V works

MFU-V uses transducers that emit ultrasound energy focused at specific depths beneath the skin surface — typically 1.5, 3.0, and 4.5 mm — while a real-time imaging mode (DeepSEE) allows the operator to visualize the tissue layers being treated and confirm appropriate placement [6]. At the focal point, the absorbed energy generates a small, controlled thermal coagulation zone. Surrounding tissue is not destroyed; instead, the wound-healing response recruits fibroblasts to the coagulation zones, where new type I and III collagen and elastin are produced over the following months [1][2].

Importantly, the epidermal barrier is preserved. A 24-week biophysical evaluation in 22 women treated with MFU-V at the jawline and submentum showed no significant change in transepidermal water loss, hydration, or erythema, and skin temperature remained within physiologic range three days after treatment [4]. The same study documented a significant increase in measured skin elasticity at weeks 12 and 24 compared with baseline.

Expected timeline

The clinical evidence consistently describes a delayed onset and a gradual build of effect:

• 0–14 days: transient edema and tenderness can occur; objective measures of laxity may show no improvement in this window.
• 30 days: early improvement in laxity grading and global aesthetic improvement scale (GAIS) scores is detectable in many trials [3].
• 90 days: lift and tightening effects are typically more visible.
• 180 days: outcomes in randomized trials are commonly reported at this endpoint; elasticity measurements remain improved versus baseline at this time [3][4].
• 48 weeks and beyond: combination evaluations have documented sustained skin firmness and thickness improvements approximately one year after a single session, especially when MFU-V is combined with appropriate volumizing strategies [2].

Patients should be counseled that meaningful results unfold over 3 to 6 months and are not visible immediately after a session.

Comparative evidence with monopolar radiofrequency

For a deeper look at monopolar radiofrequency, see our companion article on Thermage and monopolar RF skin tightening.

A randomized, split-face, evaluator-blind trial of 20 subjects compared monopolar radiofrequency (MRF) on one side of the face with MFU-V on the other and followed subjects for six months [3]. Both modalities produced significant improvement on the Fasil Face and Neck Laxity Rating scale at days 30, 90, and 180. Subject-reported Global Aesthetic Improvement Scale scores were similarly favorable on both sides. The investigators did not find a statistically significant difference between the two devices on standardized investigator measures of laxity, patient satisfaction, or adverse events. The interpretation in current practice is that MFU-V and monopolar radiofrequency are reasonable alternative approaches for mild-to-moderate laxity, with device selection driven by anatomy, depth of laxity, operator experience, and patient preference rather than by an overall efficacy gap [3].

Adverse events and limitations

Across the 67-study narrative review of MFU-V published in 2025, adverse events were generally described as rare and transient [2]. Reported events include:

• Procedural pain during treatment, which is typically managed with topical anesthesia and titration of energy settings.
• Erythema and edema in the hours to days after treatment, which resolve without intervention.
• Transient bruising along the treatment zone.
• Rare reports of transient sensory changes (numbness or paresthesia) and, very rarely, temporary motor weakness when treatment is delivered too close to motor nerve branches — a recognized risk that is mitigated by appropriate visualization, depth selection, and operator training [2][6].

Limitations of the current evidence base are important to acknowledge. Many published studies are sponsored by the device manufacturer, sample sizes are often modest, and standardized outcome scales vary across trials. The Pan-Asian expert consensus explicitly notes that the proliferation of marketing claims around microfocused ultrasound technology has outpaced rigorous comparative evidence in some markets, and recommends patient selection and device choice based on peer-reviewed data rather than marketing assertions [6].

Patient selection

The Korean treatment protocol published in 2023 and the Pan-Asian expert consensus describe the following considerations [5][6]:

• Appropriate candidates: patients with mild-to-moderate skin laxity and adequate dermal thickness; Fitzpatrick skin types I–VI have been treated, with appropriate parameter selection.
• Less optimal candidates: patients with very advanced laxity who would be better served by surgical options; patients with substantial volume loss who may require combined approaches such as biostimulators or filler in addition to MFU-V.
• Contraindications and cautions: active skin infection in the treatment area, severe acne, history of keloid or hypertrophic scarring at facial sites, implanted devices in the treatment field, and pregnancy (where data is limited) are commonly cited reasons to defer or modify treatment.

How MFU-V fits into a broader plan

The 2025 skin-quality narrative review evaluated MFU-V alone and in combination with fillers and neuromodulators across four emergent perceptual categories of skin quality — firmness, surface evenness, tone evenness, and glow [2]. Firmness was the most consistently supported outcome (52 of 67 studies), while effects on tone evenness and glow were supported by a smaller number of studies. Several protocols describe MFU-V as one component of a multimodal plan rather than a single-modality solution: for example, MFU-V for laxity, biostimulators for volume, and conservative use of dermal filler for contour [2][5].

Bottom line

MFU-V is a non-invasive option for mild-to-moderate facial laxity with a consistent evidence base across more than two decades of clinical use. The procedure preserves the epidermal barrier, produces a delayed but measurable improvement in skin elasticity within 12 to 24 weeks, and has a comparable efficacy and safety profile to monopolar radiofrequency in randomized comparison [3][4]. Adverse events are typically transient, but motor-nerve safety depends on operator training and appropriate use of the visualization mode [2][6]. Patients should expect a gradual onset over months, not an immediate change, and should discuss with a board-certified dermatologist whether MFU-V is appropriate for their pattern of laxity.

This is not medical advice. Treatment decisions should be made with a qualified clinician after a complete history and examination.